Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/16/2026, 5:42:48 AM
Content snapshot
{ "session_id": "sess_SDA-2026-04-14-gap-pubmed-20260411-075338-35f913fb", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax:MiniMax-M2.7", "action": "synthesize", "content": "\n\n```json\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"hypothesis_id\": \"H5\",\n \"title\": \"HDAC9 Derepression of TFEB/LAMP2A Autophagy Genes for Enhanced Aβ Clearance\",\n \"composite_score\": 0.599,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.50,\n \"evidence_strength\": 0.50,\n \"novelty\": 0.60,\n \"feasibility\": 0.55,\n \"therapeutic_potential\": 0.75,\n \"druggability\": 0.55,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"TFEB is a master regulator of autophagy-lysosomal pathway genes; activation reduces Aβ accumulation\", \"pmid\": \"24786306\"},\n {\"claim\": \"HDAC9 depletion enhances autophagic activity through derepression of autophagy genes\", \"pmid\": \"25938942\"},\n {\"claim\": \"Lysosomal dysfunction is a hallmark of AD; enhancing CTSD activity reduces Aβ plaques in APP/PS1 mice\", \"pmid\": \"22138152\"},\n {\"claim\": \"Class IIa HDACs (particularly HDAC4/5) inhibit autophagy via repression of TFEB target genes\", \"pmid\": \"20802524\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Class IIa HDACs INHIBIT autophagy (Huang et al.); HDAC9 overexpression would be predicted to reduce autophagy, contradicting hypothesis\", \"pmid\": \"20802524\"},\n {\"claim\": \"Comprehensive HDAC9 knockdown in neurons does not alter TFEB target genes\", \"pmid\": \"30463949\"},\n {\"claim\": \"Late-stage AD neurons have severely impaired lysosomal acidification and autophagosome-lysosome fusion deficits\", \"pmid\": \"23333986\"},\n {\"claim\": \"Increased autophagy in neurons can be detrimental, leading to autophagic cell death\", \"pmid\": \"31505758\"}\n ],\n \"key_citations\": [\"24786306\", \"25938942\", \"22138152\", \"20802524\", \"30463949\", \"23333986\"],\n \"recommended_experiments\": [\n \"mTOR inhibition (rapamycin) + HDAC9 overexpression additivity test for Aβ clearance\",\n \"Measure lysosomal Aβ degradation directly using Aβ(1-42) internalization assays with vs. without chloroquine\",\n \"HDAC9 ChIP-seq in human iPSC-derived neurons to assess direct TFEB target binding\"\n ]\n },\n {\n \"rank\": 2,\n \"hypothesis_id\": \"H4\",\n \"title\": \"HDAC9 Suppression of GSK3β Signaling Through PP1R1B-Mediated Synaptic Phosphatase Activation\",\n \"composite_score\": 0.590,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.40,\n \"evidence_strength\": 0.35,\n \"novelty\": 0.55,\n \"feasibility\": 0.75,\n \"therapeutic_potential\": 0.55,\n \"druggability\": 0.75,\n \"safety_profile\": 0.50,\n \"competitive_landscape\": 0.70,\n \"data_availability\": 0.50,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"DARPP-32 is highly expressed in striatal and cortical neurons where it modulates synaptic plasticity via PP1 inhibition\", \"pmid\": \"10725336\"},\n {\"claim\": \"GSK3β is the primary kinase driving tau hyperphosphorylation in AD; inhibition reduces both tau pathology and Aβ toxicity\", \"pmid\": \"19561560\"},\n {\"claim\": \"PP2A activation counteracts both tau pathology and Aβ-induced synaptic dysfunction\", \"pmid\": \"20155850\"},\n {\"claim\": \"HDAC9 is expressed in cortical neurons and regulates synaptic gene programs\", \"pmid\": \"27297484\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"AD patient brains show DECREASED DARPP-32 expression, correlating with cognitive decline—opposite to predicted benefit\", \"pmid\": \"28591801\"},\n {\"claim\": \"GSK3β is primarily regulated by Akt and Wnt/β-catenin pathways, not PP1/PP2A in most contexts\", \"pmid\": \"11238895\"},\n {\"claim\": \"PP1 dephosphorylates GSK3β at Ser9 (ACTIVATING it), creating positive feedback rather than suppression\", \"pmid\": \"21845868\"},\n {\"claim\": \"DARPP-32 is highly enriched in striatum, not cortex—neuroanatomical mismatch\", \"pmid\": \"10725336\"}\n ],\n \"key_citations\": [\"10725336\", \"19561560\", \"20155850\", \"27297484\", \"28591801\", \"11238895\"],\n \"recommended_experiments\": [\n \"CRISPR knockdown of PPP1R1B in cortical neurons to test if HDAC9 benefit is DARPP-32 independent\",\n \"Demonstrate that HDAC9 effects on pTau are present in cortex despite low DARPP-32 expression\",\n \"Test additivity between HDAC9 overexpression and subeffective GSK3β inhibition\"\n ]\n },\n {\n \"rank\": 3,\n \"hypothesis_id\": \"H1\",\n \"title\": \"HDAC9-MEF2 Transcriptional Derepression of Synaptic and Neurotrophic Genes\",\n \"composite_score\": 0.593,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.55,\n \"evidence_strength\": 0.50,\n \"novelty\": 0.60,\n \"feasibility\": 0.55,\n \"therapeutic_potential\": 0.75,\n \"druggability\": 0.40,\n \"safety_profile\": 0.50,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.55,\n \"reproducibility\": 0.50\n },\n \"evidence_for\": [\n {\"claim\": \"Class IIa HDACs (HDAC4/5/7/9) lack catalytic activity and act as dominant-negative regulators of class I HDAC function\", \"pmid\": \"11896198\"},\n {\"claim\": \"MEF2C is a critical regulator of excitatory synapse development and cognitive function\", \"pmid\": \"24733992\"},\n {\"claim\": \"HDAC9 regulates MEF2-dependent transcription in muscle and neurons by controlling recruitment of co-repressors\", \"pmid\": \"12198153\"},\n {\"claim\": \"MEF2 target genes include synaptic structural proteins and neurotrophic factors critical for memory\", \"pmid\": \"15916964\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"HDAC9 deletion in mice causes INCREASED MEF2C activity through loss of MEF2-HDAC competition, suggesting bidirectional regulation\", \"pmid\": \"12435673\"},\n {\"claim\": \"Overexpression of class IIa HDACs can RECRUIT HDAC3 to chromatin via NCoR/SMRT, paradoxically increasing repression\", \"pmid\": \"11896198\"},\n {\"claim\": \"HDAC9 knockdown enhances synaptic plasticity markers, contradicting the overexpression = benefit model\", \"pmid\": \"25339752\"},\n {\"claim\": \"HDAC9 shows highest expression in muscle and heart; cortical neuronal expression is substantially lower\", \"pmid\": \"11429785\"}\n ],\n \"key_citations\": [\"11896198\", \"24733992\", \"12198153\", \"15916964\", \"12435673\", \"25339752\"],\n \"recommended_experiments\": [\n \"MEF2C-CRISPRi neurons to test if HDAC9 overexpression effects require MEF2C\",\n \"HDAC9 catalytic-dead mutant (H976A/H998A) to dissociate scaffold from catalytic function\",\n \"HDAC9 ChIP-seq in human iPSC-derived neurons for direct MEF2C co-occupancy at synaptic genes\"\n ]\n },\n {\n \"rank\": 4,\n \"hypothesis_id\": \"H3\",\n \"title\": \"HDAC9 Enhancement of ADAM10 Transcription Through MEF2 Binding Site Activation\",\n \"composite_score\": 0.503,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.45,\n \"evidence_strength\": 0.40,\n \"novelty\": 0.55,\n \"feasibility\": 0.50,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.40,\n \"safety_profile\": 0.45,\n \"competitive_landscape\": 0.45,\n \"data_availability\": 0.40,\n \"reproducibility\": 0.45\n },\n \"evidence_for\": [\n {\"claim\": \"ADAM10 is the primary α-secretase and its overexpression reduces Aβ production in vitro and in vivo\", \"pmid\": \"15961624\"},\n {\"claim\": \"ADAM10 promoter contains functional MEF2 binding sites responsive to neuronal activity\", \"pmid\": \"15916964\"},\n {\"claim\": \"MEF2C activity directly correlates with ADAM10 expression in human neurons\", \"pmid\": \"24733992\"},\n {\"claim\": \"Class IIa HDACs regulate genes involved in ectodomain shedding (ChIP-Atlas dataset)\", \"pmid\": \"27297484\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"ADAM10 promoter analysis reveals predominant regulation by RAREs and AP1 sites, not MEF2\", \"pmid\": \"21282465\"},\n {\"claim\": \"MEF2C expression in human neurons does not correlate with ADAM10 protein levels in AD patient cohorts\", \"pmid\": \"25611513\"},\n {\"claim\": \"HDAC inhibitors REDUCE ADAM10 expression through promoter hypermethylation\", \"pmid\": \"19570590\"},\n {\"claim\": \"Reliance on computational ChIP-Atlas data without experimental validation\", \"pmid\": \"ChIP-Atlas\"}\n ],\n \"key_citations\": [\"15961624\", \"15916964\", \"24733992\", \"21282465\", \"25611513\", \"19570590\"],\n \"recommended_experiments\": [\n \"HDAC9 ChIP-seq in primary human neurons showing direct ADAM10 promoter occupancy\",\n \"MEF2 binding site mutation in ADAM10 promoter reporter to test HDAC9 responsiveness\",\n \"ADAM10 haploinsufficiency to block HDAC9's Aβ-reducing effect\"\n ]\n },\n {\n \"rank\": 5,\n \"hypothesis_id\": \"H6\",\n \"title\": \"HDAC9 Epigenetic Activation of LRP1 Expression to Enhance Neuronal Aβ Uptake and Degradation\",\n \"composite_score\": 0.466,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.40,\n \"evidence_strength\": 0.35,\n \"novelty\": 0.55,\n \"feasibility\": 0.40,\n \"therapeutic_potential\": 0.60,\n \"druggability\": 0.35,\n \"safety_profile\": 0.50,\n \"competitive_landscape\": 0.40,\n \"data_availability\": 0.35,\n \"reproducibility\": 0.40\n },\n \"evidence_for\": [\n {\"claim\": \"LRP1 mediates neuronal uptake and degradation of Aβ; neuron-specific LRP1 deletion exacerbates plaque deposition\", \"pmid\": \"20448228\"},\n {\"claim\": \"Aβ-LRP1 interaction activates Akt signaling, promoting neuronal survival\", \"pmid\": \"19229321\"},\n {\"claim\": \"Class IIa HDAC overexpression in endothelial cells upregulates LRP1 expression\", \"pmid\": \"22302837\"},\n {\"claim\": \"LRP1 promoter contains functional MEF2 binding sites (ENCODE ChIP-seq data)\", \"pmid\": \"ENCODE\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"Neuronal LRP1 is regulated primarily by neuronal activity via NGF/BDNF signaling, not class IIa HDACs\", \"pmid\": \"11826130\"},\n {\"claim\": \"HDAC9 knockdown in cortical neurons does not alter LRP1 mRNA (RNA-seq dataset)\", \"pmid\": \"GSE120895\"},\n {\"claim\": \"Evidence from PMID:22302837 is in endothelial cells, not neurons—fundamentally different regulation\", \"pmid\": \"22302837\"},\n {\"claim\": \"LRP1 promoter has multiple transcriptional start sites and complex regulation by SP1, EGR1, NF-κB\", \"pmid\": \"30629088\"}\n ],\n \"key_citations\": [\"20448228\", \"19229321\", \"22302837\", \"11826130\", \"GSE120895\"],\n \"recommended_experiments\": [\n \"LRP1 knockout neurons to test if HDAC9 benefit requires LRP1\",\n \"LRP1 promoter MEF2 binding site mutation in luciferase assay\",\n \"Test whether HDAC9 effects on LRP1 are secondary to synaptic activity improvements\"\n ]\n },\n {\n \"rank\": 6,\n \"hypothesis_id\": \"H2\",\n \"title\": \"HDAC9 Repression of BACE1 Transcription via FOXP2-Mediated Recruitment\",\n \"composite_score\": 0.344,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.35,\n \"evidence_strength\": 0.40,\n \"novelty\": 0.50,\n \"feasibility\": 0.30,\n \"therapeutic_potential\": 0.25,\n \"druggability\": 0.20,\n \"safety_profile\": 0.30,\n \"competitive_landscape\": 0.25,\n \"data_availability\": 0.35,\n \"reproducibility\": 0.35\n },\n \"evidence_for\": [\n {\"claim\": \"FOXP2 represses BACE1 transcription and reduces Aβ production in neuronal cell models\", \"pmid\": \"21670307\"},\n {\"claim\": \"FOXP2 interacts with HDAC9 in neuronal nuclei and cooperatively regulates language-related genes\", \"pmid\": \"20937708\"},\n {\"claim\": \"HDAC9 localizes to transcriptionally active chromatin regions in neurons\", \"pmid\": \"27297484\"},\n {\"claim\": \"BACE1 elevation is sufficient to drive Aβ overproduction in AD mouse models\", \"pmid\": \"11160738\"}\n ],\n \"evidence_against\": [\n {\"claim\": \"HDAC9-FOXP2 interaction studies focus on LANGUAGE-related genes, not amyloid processing genes\", \"pmid\": \"20937708\"},\n {\"claim\": \"BACE1 transcription is predominantly regulated by STAT1, AP1, and YY1—no established MEF2 binding\", \"pmid\": \"19131512\"},\n {\"claim\": \"FOXP2 represses BACE1 only under specific extracellular matrix conditions; under standard culture, repression is minimal\", \"pmid\": \"21670307\"},\n {\"claim\": \"Mechanistically paradoxical: claims HDAC9 recruits H3K27 demethylases (activating modifiers) to achieve transcriptional suppression\", \"pmid\": \"27297484\"},\n {\"claim\": \"FOXP2 is highly enriched in basal ganglia, not hippocampus/association cortex—wrong brain region for Aβ pathology\", \"pmid\": \"16631373\"}\n ],\n \"key_citations\": [\"21670307\", \"20937708\", \"27297484\", \"11160738\", \"19131512\", \"16631373\"],\n \"recommended_experiments\": [\n \"BACE1 promoter luciferase reporter with HDAC9 overexpression to test direct effect\",\n \"CRISPR knockout of FOXP2 to block HDAC9-mediated BACE1 suppression\",\n \"DEPRECATED: BACE1 inhibitor programs abandoned due to liver toxicity and cognitive worsening\"\n ]\n },\n {\n \"rank\": 7,\n \"hypothesis_id\": \"H7\",\n \"title\": \"HDAC9 Suppression of Neuroinflammation Through NF-κB Pathway Inhibition in Disease-Associated Microglia\",\n \"composite_score\": 0.464,\n \"dimension_scores\": {\n \"mechanistic_plausibility\": 0.30,\n \"evidence_strength\": 0.30,\n \"novelty\": 0.50,\n \"feasibility\": 0.55,\n \"therapeutic_potential\": 0.50,\n \"druggability\": 0.50,\n \"safety_profile\": 0.50,\n \"competitive_landscape\": 0.50,\n \"data_availability\": 0.35,\n \"reproducibility\": 0.35\n },\n \"evidence_for\": [\n {\"claim\": \"Class IIa HDACs directly interact with NF-κB p65 and suppress inflammatory gene transcription in macrophages\", \"pmid\": \"17928808\"},\n {\"claim\": \"MEF2 proteins compete with NF-κB for limited CBP/p300 pools; MEF2 activation suppresses inflammatory responses\", \"pmid\": \"15737940", "tokens_used": "3511", "persona_id": "persona-synthesizer" }